Characteristic | Value |
---|---|
Age at diagnosis (range) / years old | 44 (20–71) |
No. of patients by gender | |
Male | 33 (67.3%) |
Female | 16 (32.7%) |
No. of patients by T stage | |
T4 | 11 (22.4%) |
T3 | 29 (59.2%) |
T2 | 7 (14.3%) |
T1 | 2 (4.1%) |
No. of patients by N stage | |
N3 | 5 (10.2%) |
N2 | 26 (53.1%) |
N1 | 18 (36.7%) |
N0 | 0 (0.0%) |
No. of patients by WHO pathologic subtypes | |
I-II | 0 (0.0%) |
III | 100 (100.0%) |
No. of patients by prior allergic rhinitis | |
Yes | 3 (6.1%) |
No | 46 (93.9%) |
No. of patients by chronic smokers | |
Yes | 9 (18.4%) |
No | 40 (81.6%) |
No. of patients by treatment modes | |
RT | 2 (4.1%) |
RT + CCT | 12 (24.5%) |
NACT + RT + CCT | 35 (71.4%) |
Prescribed total dose (range) / Gy | 70.00 (66.00–74.00) |
Prescribed single dose (range) / Gy | 2.19 (2.06–2.34) |
Actual maximum GTV dose (range) / Gy | 77.22 (73.77–83.50) |
Actual minimum GTV dose (range) / Gy | 69.79 (65.27–72.59) |
Actual mean GTV dose (range) / Gy | 73.75 (65.80–78.66) |
No. of patients by RICS sides | |
Right | 24 (49.0%) |
Left | 25 (51.0%) |
SNOT-22 score (range) | 17 (11–59) |